↓ Skip to main content

The Crossroads of Cancer Epigenetics and Immune Checkpoint Therapy

Overview of attention for article published in Clinical Cancer Research, December 2022
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter
20 tweeters

Readers on

mendeley
3 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The Crossroads of Cancer Epigenetics and Immune Checkpoint Therapy
Published in
Clinical Cancer Research, December 2022
DOI 10.1158/1078-0432.ccr-22-0784
Pubmed ID
Authors

Goran Micevic, Marcus W. Bosenberg, Qin Yan

Abstract

Immune checkpoint inhibitors (ICI) have significantly improved treatment outcomes for several types of cancer over the past decade, but significant challenges that limit wider effectiveness of current immunotherapies remain to be addressed. Certain 'cold' tumor types, such as pancreatic cancer, exhibit very low response rates to ICI due to intrinsically low immunogenicity. Additionally, many patients who initially respond to ICI lack a sustained response due to T-cell exhaustion. Several recent studies show that epigenetic modifiers, such as SETDB1 and LSD1, can play critical roles in regulating both tumor cell-intrinsic immunity and T-cell exhaustion. Here, we review the evidence showing that multiple epigenetic regulators silence the expression of endogenous antigens, and their loss induces viral mimicry responses bolstering the response of 'cold' tumors to ICI in pre-clinical models. Similarly, a previously unappreciated role for epigenetic enzymes is emerging in the establishment and maintenance of stem-like T-cell populations that are critical mediators of response to ICI. Targeting the crossroads of epigenetics and immune checkpoint therapy has tremendous potential to improve anti-tumor immune responses and herald the next generation of sustained responses in immuno-oncology.

Twitter Demographics

The data shown below were collected from the profiles of 20 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 3 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 3 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 2 67%
Student > Ph. D. Student 1 33%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 2 67%
Unspecified 1 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 January 2023.
All research outputs
#2,419,687
of 23,039,416 outputs
Outputs from Clinical Cancer Research
#2,042
of 12,651 outputs
Outputs of similar age
#44,293
of 413,606 outputs
Outputs of similar age from Clinical Cancer Research
#26
of 108 outputs
Altmetric has tracked 23,039,416 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,651 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.9. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 413,606 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 108 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.